JP2017519781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519781A5 JP2017519781A5 JP2016575362A JP2016575362A JP2017519781A5 JP 2017519781 A5 JP2017519781 A5 JP 2017519781A5 JP 2016575362 A JP2016575362 A JP 2016575362A JP 2016575362 A JP2016575362 A JP 2016575362A JP 2017519781 A5 JP2017519781 A5 JP 2017519781A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 150000003839 salts Chemical class 0.000 claims 40
- 125000000547 substituted alkyl group Chemical group 0.000 claims 9
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- -1 substituted Chemical class 0.000 claims 3
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 2
- 150000001345 alkine derivatives Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000003053 piperidines Chemical class 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical class NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018365P | 2014-06-27 | 2014-06-27 | |
| US62/018,365 | 2014-06-27 | ||
| PCT/US2015/038089 WO2015200843A1 (en) | 2014-06-27 | 2015-06-26 | Inhibitors of lysine specific demethylase-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087186A Division JP6851418B2 (ja) | 2014-06-27 | 2019-05-03 | リジン特異的なデメチラーゼ−１の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519781A JP2017519781A (ja) | 2017-07-20 |
| JP2017519781A5 true JP2017519781A5 (cg-RX-API-DMAC7.html) | 2018-08-09 |
| JP6587241B2 JP6587241B2 (ja) | 2019-10-09 |
Family
ID=54938856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575362A Expired - Fee Related JP6587241B2 (ja) | 2014-06-27 | 2015-06-26 | リジン特異的なデメチラーゼ−１の阻害剤 |
| JP2019087186A Expired - Fee Related JP6851418B2 (ja) | 2014-06-27 | 2019-05-03 | リジン特異的なデメチラーゼ−１の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087186A Expired - Fee Related JP6851418B2 (ja) | 2014-06-27 | 2019-05-03 | リジン特異的なデメチラーゼ−１の阻害剤 |
Country Status (28)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016002496B1 (pt) | 2013-08-06 | 2022-07-12 | Imago Biosciences Inc. | Composto e composição farmacêutica |
| LT3160956T (lt) | 2014-06-27 | 2020-09-10 | Celgene Quanticel Research, Inc. | Lizinui specifinės demetilazės-1 inhibitoriai |
| EA201891526A3 (ru) * | 2014-07-03 | 2019-05-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической деметилазы-1 |
| ES3005884T3 (en) | 2015-02-12 | 2025-03-17 | Imago Biosciences Inc | A kdm1a inhibitor and its use in therapy |
| US20180284095A1 (en) | 2015-06-12 | 2018-10-04 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| CA3017411C (en) | 2016-03-15 | 2024-06-25 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| EP3430015B9 (en) | 2016-03-16 | 2025-12-31 | Oryzon Genomics, S.A. | METHODS FOR DETERMINING THE ENGAGEMENT OF A KDM1A TARGET AND CORRESPONDING USEFUL CHEMOPROBE |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2018035259A1 (en) | 2016-08-16 | 2018-02-22 | Imago Biosciences, Inc. | Methods and processes for the preparation of kdm1a inhibitors |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| JP7089506B2 (ja) * | 2017-04-10 | 2022-06-22 | 三井化学アグロ株式会社 | ピリドン化合物を有効成分として含有する抗真菌剤およびその使用方法 |
| JP2020121925A (ja) * | 2017-04-10 | 2020-08-13 | 三井化学アグロ株式会社 | ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物 |
| JP7071962B2 (ja) * | 2017-04-10 | 2022-05-19 | 三井化学アグロ株式会社 | ピリドン化合物と有害生物防除剤を含有する有害生物防除組成物および有害生物の防除方法 |
| AU2018309372B2 (en) | 2017-08-03 | 2024-08-15 | Oryzon Genomics, S.A. | Methods of treating behavior alterations |
| JP7265275B2 (ja) * | 2018-03-21 | 2023-04-26 | スージョウ プーヘー バイオファーマ カンパニー リミテッド | Ｓｈｐ２阻害剤およびその使用 |
| AU2019265022B2 (en) * | 2018-05-11 | 2024-08-15 | Imago Biosciences, Inc. | KDM1A inhibitors for the treatment of disease |
| AU2020242302B2 (en) | 2019-03-20 | 2025-10-30 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| AU2022254484A1 (en) | 2021-04-08 | 2023-11-09 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4419504A4 (en) * | 2021-10-18 | 2025-09-03 | Imago Biosciences Inc | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| KR20250109775A (ko) | 2022-11-24 | 2025-07-17 | 오리존 지노믹스 에스.에이. | 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1861399B1 (en) | 2005-03-14 | 2011-12-14 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
| BRPI0711674A2 (pt) * | 2006-06-21 | 2011-11-16 | Du Pont | Método de inibição da proliferação indesejada, composto, composição e método de inibição |
| HRP20141174T1 (hr) * | 2007-06-27 | 2015-02-13 | Astrazeneca Ab | Derivati pirazinona i njihova uporaba za lijeäśenje bolesti pluä†a |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| WO2012013727A1 (en) * | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| JP6215315B2 (ja) | 2012-06-12 | 2017-10-18 | アッヴィ・インコーポレイテッド | ピリジノンおよびピリダジノン誘導体 |
| FI3080100T3 (fi) * | 2013-12-11 | 2023-03-15 | Celgene Quanticel Res Inc | Lysiinispesifisen demetylaasi-1:n estäjät |
| CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
| HRP20220096T1 (hr) * | 2014-05-01 | 2022-04-15 | Celgene Quanticel Research, Inc. | Inhibitori lizin specifične demetilaze-1 |
| LT3160956T (lt) | 2014-06-27 | 2020-09-10 | Celgene Quanticel Research, Inc. | Lizinui specifinės demetilazės-1 inhibitoriai |
-
2015
- 2015-06-26 LT LTEP15811526.1T patent/LT3160956T/lt unknown
- 2015-06-26 JP JP2016575362A patent/JP6587241B2/ja not_active Expired - Fee Related
- 2015-06-26 BR BR112016030697-0A patent/BR112016030697B1/pt not_active IP Right Cessation
- 2015-06-26 EP EP15811526.1A patent/EP3160956B1/en active Active
- 2015-06-26 SI SI201531328T patent/SI3160956T1/sl unknown
- 2015-06-26 EA EA201692513A patent/EA030946B1/ru unknown
- 2015-06-26 US US15/322,277 patent/US10011583B2/en active Active
- 2015-06-26 CA CA2953810A patent/CA2953810C/en active Active
- 2015-06-26 ES ES15811526T patent/ES2812626T3/es active Active
- 2015-06-26 RS RS20200980A patent/RS60658B1/sr unknown
- 2015-06-26 HU HUE15811526A patent/HUE050564T2/hu unknown
- 2015-06-26 WO PCT/US2015/038089 patent/WO2015200843A1/en not_active Ceased
- 2015-06-26 KR KR1020177000953A patent/KR102438302B1/ko active Active
- 2015-06-26 AU AU2015279591A patent/AU2015279591A1/en not_active Abandoned
- 2015-06-26 DK DK15811526.1T patent/DK3160956T3/da active
- 2015-06-26 MX MX2017000179A patent/MX376632B/es active IP Right Grant
- 2015-06-26 HR HRP20201337TT patent/HRP20201337T1/hr unknown
- 2015-06-26 PL PL15811526T patent/PL3160956T3/pl unknown
- 2015-06-26 SG SG10201911220TA patent/SG10201911220TA/en unknown
- 2015-06-26 SM SM20200443T patent/SMT202000443T1/it unknown
- 2015-06-26 PT PT158115261T patent/PT3160956T/pt unknown
- 2015-06-26 SG SG11201610866PA patent/SG11201610866PA/en unknown
- 2015-06-26 CN CN201580046216.4A patent/CN106660987B/zh not_active Expired - Fee Related
-
2016
- 2016-12-22 IL IL249733A patent/IL249733B/en active IP Right Grant
- 2016-12-27 CL CL2016003350A patent/CL2016003350A1/es unknown
-
2017
- 2017-01-04 ZA ZA2017/00069A patent/ZA201700069B/en unknown
- 2017-01-16 CO CONC2017/0000362A patent/CO2017000362A2/es unknown
- 2017-01-26 EC ECIEPI20175635A patent/ECSP17005635A/es unknown
-
2018
- 2018-05-29 US US15/991,222 patent/US10597376B2/en not_active Expired - Fee Related
-
2019
- 2019-05-03 JP JP2019087186A patent/JP6851418B2/ja not_active Expired - Fee Related
- 2019-11-07 AU AU2019261771A patent/AU2019261771B2/en not_active Ceased
-
2020
- 2020-02-03 US US16/780,704 patent/US11028066B2/en active Active
- 2020-08-14 CY CY20201100759T patent/CY1123475T1/el unknown